http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
진행성 위장관 암에 대한 5-Fluorouracil, Leucovorin 및 Mitomycin-C 복합 화학요법
김성록 인제대학교 1990 仁濟醫學 Vol.11 No.4
진행성 위장관의 악성종양에 대한 약물 치료는 아직도 만족스럽지 못하며, 유효한 경우에도 약물 치료에 따른 독성 등으로 계속 치료하기가 곤란한 경우가 많았다. 이에 저자는 아직도 위장관암의 주된 치료제인 5-Fluorouracil과 Mitomycin-C에 5-FU의 효력 증강제인 Leucovorin을 첨가하여 제2위상 시험을 한 후 그 효과와 독성을 관찰하였다. A phase II study was conducted to determine the efficacy and toxicity of 5-fluorouracil (5-FU), low dose leucovorin (LV) and mitomycin-C (MMC) in patients (pts) with advanced gastrointestinal tract cancer. The treatment regimen consisted of 5-FU 375 mg/m2 IV over 15 minutes daily for 5 days, just after IV bolus of LV 20 mg/m2 each, and MMC IV bolus 9 mg/m2 which was reduced to 7 mg/m2 from the second cycle. The treatment was repeated every 3-4 weeks, 21 eligible pts have been entered on study. 18 pts are presently evaluable for response and toxicity ; 3 pts were lost to follow up after chemotherapy. Among 18 evaluable pts, there were 111 pts with stomach cancer, pancreas 2, bile duct 1, gall bladder 1, and colon 3. 17 patients had adenocarcinoma ; 1 bile duct cancer was not confirmed pathologically. The median alee was 57 (Range 37-84) years. 3 pts had 5-FU containing chemotherapy previously. The pts on this trial received a median of 2 cycles (range 1-7). 1pt (bile duct) had radiotherapy of 800 cGy after chemotherapy. There were partial reponses (stomach 7, pancreas 1) tasting 1-7+months and 3 objective responses (for "evaluable disease". stomach 2, bile duct 1) lasting 1-4+months. 2 pts with stable disease or progressive disease on prior 5-FU containing chemotherapy had partial responses. 5 pts were in stable disease and 2 in progressive desease. 2 pts died so far ; one in one month with progressive disease and the other in 6 months after treatment, with the remission duration of 4 months. Toxicities were tolerable ; no one was hospitalized due to toxicity. Grade (G) 1 nausea / emesis was observed in 4 pts and G 2 in 1 pt. G 2 mucositis in 3 pts, diarrhea G 1 in 2 pts and G 2 in 1 pt were noted. Granulocytopenia G 1 in 4 pts, G 3 in 2 pts and G 4 in 1 pt (who had radiotherapy), and G 1 thrombocytopenia in 2 pts were observed. This appears to be a well tolerated regimen having comparable effects. The study continues to accrue pts to better define the response rates and effects on survival.
만성 활동성 간염에 있어서 Ursodeoxycholic acid의 치료효과
김성록,안병철,윤영미,탁원영,곽규식,최용환,정준모 慶北大學校 醫科大學 1991 慶北醫大誌 Vol.32 No.4
The purpose of this study is to evaluate the clinical and biochemical effects of SGD-F^(R)(UDCA, Vitamin B_1, Vitamin B_2 complex) in chronic active hepatitis. Observed cases were given orally after each meal(three times a day) for 4 weeks. The results were as follows: 1. Among subjective symptoms, improvement rate showed in easy fatigability 86.7%, anorexia 68.0%, indigestion 80.0%, nausea and vomiting 72.7%, RUQ pain 83.3%. 2. Biochemical parameters such as SGOT, SGPT, showed to be improved significantly after the 4 weeks treatment.(p<0.01) 3. There was no specific side effect during the study period in all cases. In conclusion, SGD-F^(R) capsule may be safe and effective for chronic active hepatitis.
위장관계 종양의 Estrogen 수용체 및 병리임상학 연구 : 위암을 중심으로 in Stomach Cancer Cases
김성록,조혜제,김홍용 인제대학교 1992 仁濟醫學 Vol.13 No.2
저자는 위장관계 암, 특히 위암에서의 호르몬의 역할과 호르몬요법의 가능성을 추구하기 위하여 21명의 위절제수술을 받은 환자의 위암조직에서 면역조직화학검사를 통하여 에스트로젠 수용체를 검색하여 그 임상병리적 양상과 함께 보고하는 바이다. The estrogen receptors were examined by immunohistochemical analysis(IHA) on 21 cases of resected stomach cancel. The results Were: 1.Seven out of 21 cases showed positive reaction ; Grade (G) 3 staining in 1 case, G2 in 3 and G1 in 3 cases. 2.Among positives, 1 G2 had poorly differentiated tumor (PD), 2 G2 had moderatly differentiated (MD) and 1 G2 had PD, and 3 G2 had all MD. 3.Among all 21 cases, there were 2 well differentiated tumors that were ER negative ; 5 were positive among 11 MD cases ; 2 were positive among 8 PD cases. 4.Five out of the 6 evaluable ER positives and 11 out of the 13 evaluable negatives showed NED (no evidence of disease) or responses to chemotherapy. 5.Two out of 7 patients at or older than 60 year old and 1 out of 3 patients below 40 year old were ER positve. 6.IHA was good to discern ER positive area in tumor tissue, but needed more objective parameter to assess the degree of ER positivity. 7.Concommitant assay of the other sex hormone receptors like progesterone or androgen receptor as well as further trial of ER assay, and trial with, tamoxifen and / or progesterone seemed to be necessary as further investigations for more accurate assessment of the roles of the sex hormones in the pathogenesis and the basis of the treatment of stomach cancer.
대장 직장암의 안드로젠 수용체와 Transformining growth factor-ß의 조사 및 병리 임상학적 연구
김성록,이용준,박경미 인제대학교 1996 仁濟醫學 Vol.17 No.2
진행성 대장 직장암은 세포독성 항암제가 주 치료법이며, 만족스럽지가 못하다. 이에 저자들은 인체 내 조절 인자를 통한 치료 가능성을 추구하고자 먼저 그 암조직에서의 안드로젠 수용체와 Transforming growth factor-β의 존재 여부를 확인하였고, 임상적인 의미가 조사되었다. Objectives : The prognosis of the advanced colorectal cancer is poor and effect of the conventional chemotherapy has not been satisfactory. This study is to explore the possibility of hormonal therapy or cytokine therapy by assaying hormone receptor and cytokine (androgen receptor and TGF-β), and their correlation with clinicopathologic parameters. Methods: Androgen receptor and TGF- β were assayed by immunohistochemical(IHS) staining. The samples were prepared from surgical resection or biopsy. The correlations between the IHS positivity and clinical features or tumor differentiation were assessed. Results:1 The androgen receptor(AR) was negative in all 20 pt and TGF-β positive in 10(50%); 6 in 11 progesterone receptor positive patient(45%) and 4 in PR negative patient(36%). There was no significant association between the PR and TGF-β positivities. 2. There was no significant correlation between TGF- β positivity and the age, sex, tumorstage or CEA positivity at the time of diagnosis. 3. The histologic and nuclear differentiation(well, moderately and poorly differentiated) were not significantly different according to the status of the TGF- β positivity. Conclusions: This study first identified the TGF- β in colorectal cancer by immunohistological method in Korea. The androgen receptor was not positive. More study is needed to establish the role of the cytokine and hormone receptors in the pathogenesis and treatment of colorectal cancer.